Last reviewed · How we verify
NCT03480906
Eyenovia MiDD Usability Study
NA trial testing Latanoprost in Intraocular Pressure in 30 participants. Completed in 17 March 2018.
17 March 2018
Quick facts
| Lead sponsor | Eyenovia Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | other |
| Enrollment | 30 |
| Start date | 12 March 2018 |
| Primary completion | 17 March 2018 |
| Estimated completion | 17 March 2018 |
| Sites | 1 location across Panama |
Drugs / interventions tested
- Latanoprost (LATANOPROST) — full drug profile →
- Latanoprost (LATANOPROST) — full drug profile →
Conditions studied
- Intraocular Pressure — all drugs for Intraocular Pressure →
Sponsor
Eyenovia Inc. — full company profile →
Who can join
18 and older, any sex, with Intraocular Pressure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is to evaluate the usability and patient tolerability for microtherapeutic dosing of commercially available ocular medication via the Eyenovia microdose delivery system (MiDD)
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03480906
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Latanoprost
Trials testing the same drug.
- NCT06666855 — A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China · Phase 3 · active not recruiting
- NCT06239324 — Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser · Phase 1, PHASE2 · recruiting
- NCT04811326 — Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation · Phase 4 · unknown
- NCT03762369 — A Clinical Study to Evaluate the Efficacy and Safety of CKD-351 · Phase 3 · unknown
- NCT03611348 — Microneedling and Latanoprost in Acrofacial Vitiligo · Phase 2, PHASE3 · unknown
Other recruiting trials for Intraocular Pressure
Currently open trials in the same condition.
- NCT07274176 — The Effect of Graded Forced Expiration on Intraocular Pressure · NA · recruiting
- NCT06666751 — Anterior Segment Optical Coherence Tomography Microstent Positioning · active not recruiting
- NCT06016712 — The Effect of Labor on Intraocular Pressure Fluctuation in Healthy Eyes · NA · recruiting
- NCT05753137 — Acupuncture as Adjuvant Therapy for Glaucoma - Protocol for a Randomized Controlled Trial · NA · recruiting
- NCT05850936 — Effect of IOP Lowering on Progressive HM · NA · active not recruiting
Other Eyenovia Inc. trials
Trials by the same sponsor.
- NCT06217796 — Safety and Efficacy of Fixed Combination Phenylephrine-Tropicamide for Pupil Dilation · Phase 4 · completed
- NCT05114486 — Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults · Phase 3 · completed
- NCT04907474 — Evaluation of Pupil Dilation Speed With the MAP Dispenser · Phase 4 · completed
- NCT04657172 — Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults · Phase 3 · completed
- NCT03942419 — Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression · Phase 3 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03480906 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eyenovia Inc.
- Last refreshed: 26 July 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03480906.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing